SAN JOSE, Calif., Nov. 5, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced that the United States Patent and Trademark Office
(USPTO) has issued US Patent No. 10,463,724 titled "Breast Cancer
Vaccine."
The lead inventor on the patent is Dr. Vincent Tuohy of the Department of Inflammation
and Immunity at the Cleveland Clinic's Lerner Research Institute
and also the Mort and Iris November Distinguished Chair in
Innovative Breast Cancer Research. The patent is assigned to
the Cleveland Clinic and Anixa Biosciences is the exclusive
world-wide licensee. This patent is one of several patents and
patent applications in the portfolio licensed to Anixa Biosciences
from the Cleveland Clinic, covering the innovative breast cancer
vaccine technology.
"We are pleased that this key patent has been issued for
technology, which we hope may eliminate breast cancer," stated Dr.
Amit Kumar, Chief Executive Officer
of Anixa. "This patent covers Dr. Tuohy's method of protecting
women from developing breast cancer by vaccinating against a
protein that is "retired" from service after a woman has stopped
lactating, only to reappear later in life in many forms of breast
cancer, especially triple negative breast cancer (TNBC), the most
lethal form of the disease. We look forward to progressing towards
major breakthroughs in the prevention of breast cancer."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not statements
of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-patent-issued-for-its-breast-cancer-vaccine-300951321.html
SOURCE Anixa Biosciences, Inc.